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Hepatitis C virus (HCV) establishes persistent infection in the majority of infected individuals. The currently accepted hypothesis of
immune evasion by antigenic variation in hypervariable region 1 (HVR1) of glycoprotein E2 does not however, explain the lack of
subsequent immune recognition. Here, we show that the N-terminal region of E2 is antigenically and structurally similar to human
immunoglobulin (Ig) variable domains. E2 is recognized by anti-human IgG antibodies and also possesses common amino acid (aa) sequence
features of the conserved v-gene framework regions of human Ig light chains in particular but also heavy chains and T cell receptors. Using a
position specific scoring system, the degree of similarity of HVR1 to Ig types correlated with immune escape and persistence in humans and
experimentally infected chimpanzees. We propose a unique role for threshold levels of Ig molecular mimicry in HCV biology that not only
advances our concept of viral immune escape and persistent infection but also provides insight into host-dependent disease patterns.
D 2004 Elsevier Inc. All rights reserved.
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Hepatitis C virus (HCV) currently infects 170 million
people constituting a major cause of chronic hepatitis,
cirrhosis, and hepatocellular carcinoma (Alter and Seeff,
2004; Major et al., 2004). HCV is the only RNA virus
infecting humans (excepting retroviruses) that persists in the
majority of infected individuals. Viruses, especially those
with RNA genomes, can undergo mutation at high
frequencies, and under novel selective pressures, rapidly
generate populations of viral variants. Such variability can0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: yu-wen.hu@bloodservices.ca (Y.-W. Hu).provide a means of evading clearance by both T- and B-cell
immunity. Accumulated data suggest that hypervariable
region 1 (HVR1), located in a stretch of 27–31 residues at
the amino terminus of the second envelope glycoprotein
(E2) is the main target of the anti-HCV neutralizing
response and therefore plays a significant role in the
establishment of viral persistence (Farci et al., 2000; Kato,
2001). During HCV infection, amino acid substitutions in
HVR1 generates populations of genetically related variants,
termed quasispecies (Domingo et al., 1997; Ducoulombier
et al., 2004; Hijikata et al., 1991), some of which are
antibody escape mutants that are not recognized by the
immune response and persist after seroconversion (Kato,
2001; Pavio and Lai, 2003). Although this is the most
accepted hypothesis, the important question as to why the
virus epitopes within HVR1 cannot be subsequently
recognized by the immune system is unknown. The role
of HVR1 in persistence has become controversial because
recombinant HCV lacking HVR1, can persist in chimpan-
zees, but the resultant virus was not able to establish05) 538–549
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decreased ability in this regard (Forns et al., 2000).
Molecular mimicry, where viruses express proteins that
are structurally similar to host defense proteins and
immunomodulators, is an important immune-evasion strat-
egy used to promote survival and persistence, especially in
DNA viruses (Ploegh, 1998; Seet et al., 2003; Vossen et al.,
2002). HCV is also known to employ molecular mimicry to
resist type I IFN (Taylor et al., 2000). The virally induced
antiviral cytokine, type I interferon (IFN), acts in part
through the dsRNA-dependent protein kinase (PKR) to
inhibit protein synthesis through phosphorylation of eukary-
otic initiation factor 2a, (eIF2a). The HCVenvelope protein
E2 contains a 12 aa sequence identical to phosphorylation
domains of both eIF2a and the PKR kinase (Taylor et al.,
1999). This domain operates to prevent PKR-dependent
phosphorylation of eIF2a and inhibition of protein syn-
thesis. The extent of PKR-eIF2a homology of this domain
correlates with the ability of HCV to resist type I IFN
treatment.
We reasoned that other instances of molecular mimicry,
targeted to other human proteins, could also be contributing
to HCV persistent infection. We found a second instance of
molecular mimicry, where HCV encodes a sequence in E2
that is homologous to human immunoglobulins (Ig), andFig. 1. Anti-human-IgG Binds HCV E2. (A) Full length HCV 3a E2 (aa1–322) or a
E. coli. The left panel shows total protein staining as a sample loading control (
binding. Samples: U-uninduced HCV 3a clone B-d8-1 (aa1–322), 1—HCV 3a B-
HCV 1a A-9 (aa1–123). In addition to the specific E2 proteins, two E. coli prote
terminal fragments of HCV1a were cloned and expressed in baculovirus infected
binding to anti-his6 antibody and the right panel is stained with anti-human-IgG Fa
1a A19 (aa1–113); 2—HCV 1a A-5 (aa1–123).specifically possesses typical structural features of the
variable region of Ig such that it cross-reacts with anti-
human-IgG. Using a bioinformatic and evolutionary
approach, sequence analysis of HCV variants that arise in
the course of primary infection in humans and chimpanzees
showed that the degree of similarity of HVR1 or its epitopes
with Ig types was directly related to viral escape and
persistence in a host specific manner, indicating a significant
role for viral molecular mimicry.Results
E2 is structurally similar to IgG
To elucidate the mechanism of immune escape by HCV,
an investigation of E2 mimicry was performed. Surprisingly,
full-length recombinant HCV genotype 3a E2 proteins
expressed in Escherichia coli (E. coli) were repeatedly seen
to bind antibody to human IgG Fab fragment (Fig. 1A, lanes
1 and 2), suggesting structural similarity between E2 and
human Ig molecules. This binding was also obtained when
using the first 113 or 123 aa of E2 (encompassing
hypervariable regions 1 and 2 (HVR1, HVR2)) from
different HCV variants of genotype 1a whether synthesizedmino terminal regions from aa1–123 of HCV 1a proteins were expressed in
Coomassie blue) and the right panel shows anti human-IgG Fab fragment
1 (aa1–322), 2—HCV 3a B-2 (aa1–322); 3—HCV 1a A-5 (aa1–123); 4—
in bands were observed to bind anti-human IgG (open arrows). (B) Amino
insect cells. The left panel shows the loading controls that were detected by
b fragment. Sample C—cell lysate from empty baculovirus vector; 1—HCV
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against the Fab fragment (Fig. 1A lanes 3, 4; and 1B lanes 1,
2) or whole human IgG (not shown), indicating that the
immunoglobulin antigenic cross-reactivity involves the
protein component of the N-terminal portion of E2. Most
importantly, these results satisfy the operational definition of
mimicry (Cohen, 2004) and demonstrate the Ig-like nature
of the N-terminal portion of E2, since both Ig and E2 are
bound by common ligands (i.e., anti-IgG antibodies).
Sequence alignment of E2 with immunoglobulin and T cell
receptors
To assess the nature of the structural similarities between
E2 and Igs, an alignment between N-terminal portions of a
variety of E2 sequences representing the six major HCV
genotypes and sequences of various Ig types was executed.
As a first step, computer-generated alignments (i.e., BLAST
and ClustalW) were used to identify sequence similarities
between E2 and conserved Ig aas. The regions of highest
sequence similarity were found to be almost exclusively
restricted to the variable region (v-gene) of Ig molecules and
the first 104 aa of E2. Secondly, to better align these
sequences, the Immunogenetics (IMGT) unique numbering
system (Lefranc et al., 2003) was used because it allows
comparison among members of the Ig superfamily (Barclay,
2003; Harpaz and Chothia, 1994). This numbering is
derived from the sequence alignment and 3-dimensional
structural comparisons of Ig superfamily members and
provides a definition of the highly conserved framework
regions (FR) that support the antibody binding site formed
by complementarity determining regions (CDR). Therefore
in the IMGT numbering system, conserved amino acids
always have the same number and position for immunoglo-
bulins and Ig superfamily v-like genes. The numbering
system accommodates the longest forms of CDR which are
placed in justified alignments between the framework
regions as shown for heavy, light and TCR in Fig. 2.
We were able to identify amino acids in each human Ig
framework region that were completely conserved among
E2 and Ig types (i.e., kappa light chain). These E2 positions
(IMGT numbering: G16, L53, Y55, G70, R75, Y103, and C104)
then served as references to manually complete the IMGT
formatted alignment with the FR regions of immunoglobu-
lins and TCR. It was thus possible to align FR1, FR2, and
FR3 with corresponding regions in E2 which also resulted
in alignment of intervening sequence regions that were the
same or comparable lengths to the CDR1 and CDR2 of
heavy and light immunoglobulin chains. In addition, the
insertion of a single gap before aa position 103 was
necessary to achieve the most parsimonious alignment
because the E2 sequences were 6 aas longer than the
corresponding Ig region (Fig. 2A).
The majority of aa positions in E2 matched identical aa
found among Ig members (masked in Fig. 2A), and most of
the highly conserved Ig aa are preserved in E2 (red aa inFig. 2A). Significantly, a signature sequence comprised of
14 aa positions was highly maintained (N70% identity),
among E2 sequences and all or individual Ig protein types
including the heavy and the light (kappa and lambda) Ig
chains as well as T cell receptor (TCR) a and h chains (see
red bars in Fig. 2B). In the highly conserved sites with less
than 100% conservation at aa21 and 80, alternative amino
acids of similar chemistry were in common with IG and
TCR groups (masked in blue Fig. 2). Amino acid identity
and sequence spacing of FR and CDR regions indicated a
closer relationship to kappa light chains (for example 24%
identity of HCV 2a AAF59944.1 with kappa X59312, Fig.
2), than for the heavy and TCRa and TCRh chains genes
(P b 0.0001) suggesting specific rather than random
relationships of E2 to Ig gene types. There were 20 sites
that had N50% common identity and several other sites had
highly conserved chemistry (i.e., aa26 (small hydroxyl); 50,
54, 76, 94 (hydrophobic); and 74 (acidic)). The sequence
identity of E2 to kappa light chains was significantly higher
than calculated for random sequences (P V 4  1072); and
more importantly randomized Ig consensus sequences (P V
1  109). Taken together these data indicate a conserved
core structure among E2 and Ig-like genes rather than a
chance association of amino acids in the variable CDR
regions.
Such a level of sequence similarity was also reported
between human cytomegalovirus UL18 and MHC-1 pro-
teins (Beck and Barrell, 1988), where the viral protein acts
as an MHC-1-like immunomodulator (Mocarski, 2002). The
observation of shared antigenic and sequence structures
between E2 and Ig suggests that this region of E2 has the
ability to form the basic Ig fold structure (Barclay, 2003;
Harpaz and Chothia, 1994) thus providing further support
for an Ig-like nature of the N-terminal domain of E2 (Fig. 3).
Indeed, three-dimensional modeling shows an overlap of FR
regions of the kappa variable domain (in yellow in Fig. 3A)
with E2 (superimposed in blue and red), including HVR1 (in
red), where all the framework regions align within 2 A˚ of the
kappa peptide chain. The corresponding regions of E2
possess other common features of immunoglobulin frame-
work regions such as amino acid content (high S, T and A)
as well as specific motifs such as 14SPG17, 53LFYRNN58,
85TDF87, 103YC104. Although the E2 structure does not
maintain the conserved disulfide bond of Ig formed by C23
and C104 that is guarded by W41, the modeled E2 structure
has C41 adjacent to C104 that may form an alternative di-
sulfide bond (data not shown), as occurs for some members
of the Ig superfamily (Barclay, 2003). The occurrence of aa
sequence identities, in combination with shared antigenicity
further supports the contention that E2 is a molecular mimic
of immunoglobulins.
Evolution of E2 is directional with respect to Ig
The existence of Ig similarity in E2 implies that sequence
variations in E2, in particular HVR1, could be directional in
Fig. 2. IMGT sequence alignment of the N-terminal domain of HCV E2 and the variable region of human immunoglobulins and T cell receptor genes. (A)
Groups of 10 sequences representing the major genotypes of E2, as well as groups of 5 expressed and 5 germ line variable gene sequences are shown for each
set of light kappa, light lambda, heavy, T cell receptor h, and T cell receptor a v-genes; (genes are named with accession numbers). The numbering of the HCV
polyprotein is shown at the top along with the location of HVR1 and HVR2. The location of the framework (FR) and complementarity determining regions
(CDRs) are shown within the IMGT numbered region at the bottom of the alignment. Amino acid sites with z70% shared identity between both E2 and any or
all Ig groups are masked in red with alternative common substitutions at these sites (of similar chemistry) shown in blue. All other instances of shared aa
identity with E2 are masked in black. Average v-gene region identities of E2 relative to all sequences shown (i.e., 100 pair wise comparisons for each group)
were significantly higher for the light chain genes (kappa 17.1 F 2.3%; lambda 16.3 F 2.1%) than for the heavy (11.8 F 1.8%) and TCRa (9.9 F 1.3%) and
TCRh chains (12.1 F 0.8%) genes ( P b 0.0001) indicating specific relationships of E2 Ig and TCR gene types rather than a random similarity that would not
be expected to differ among groups. (B) The percent identity to E2 is shown in the bar graph with those aa sites that share N70% identity within E2 and any Ig
group shown in red.
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threshold levels of host similarity are required for HCV
immune evasion, the patterns of E2 evolution are expected
to reflect host-dependent similarities and requirements for
change. The presence of quasispecies that differ in their
ability to be recognized by the immune system and be
cleared from the host has been observed in humans and
chimpanzees (Korenaga et al., 1997; Wyatt et al., 1998).
The only known HCV antibody neutralization sites are
located in HVR1, where aa substitutions lead to life-long
persistent infection due to escape from recognition by
preexisting anti-HVR1 antibodies (Kato et al., 1994). Given
that immunoglobulin variable regions are diverse but notrandom (Johnson and Wu, 2000), it is possible to compare
aa usage relative to groups of immunoglobulin v-genes
when formatted using the IMGT numbering system (Lefranc
et al., 2003). Using a scoring system based on a position-
specific scoring of aa similarity using the updated Dayhoff
matrix of Jones (Jones et al., 1992), (as well as other
matrices, see Methods) that quantify aa similarity, the
similarities of variant neutralizing epitopes in HVR1
sequences with respect to large groups of human Ig chains
were determined using HCV 2a variant sequences (Fig. 4A)
that were previously shown to evolve to escape immunity
(Kato et al., 1994). In these comparisons, the average sum of
similarities for each amino acid in the epitope region (aa4–
Fig. 4. Evolution of Ig mimicry during immune escape and loss of
immunogenicity of neutralizing epitopes in a human HCV 1b patient. (A)
The aa sequence of epitopes 1 and 2 (IMGT #4–14 and 7–17) in HVR1 of
sequential isolates from a previous analysis of immune escape in a patient
infected with HCV 1b (Kato et al., 1994). The sequences of the epitopes at
diagnosis and 6, 8 and 11 months post-diagnosis (PD) are shown, identity to
the original sequence is shown with dots. Serum antibody reactivity to
synthetic peptides corresponding to each sequence is indicated as (++++)
positive at 6, 8, 11 and 14 m PD.; (+++) positive at 8, 11, and 14 m; and
(++) positive at 8 and 11, or 14 m PD.; () indicates a lack of reactivity for
all time points. (B) Ig mimicry increases on immune escape and loss of
immunogenicity. The sequence of aa4–17 encompassing both overlapping
neutralizing epitopes in HVR1 was analyzed with respect to mimicry for
variant sequences selected during escape immunity are shown for each Ig
group and as an average relative to antibody binding to the variant epitopes.
Mimicry scores were significantly elevated among Ig groups for the 11-m
variants ( P = 0.031 by t test).
Fig. 3. (A) A three-dimensional model structure of the N-terminal region of
HCV. The aa sequence of the N-terminal domain of E2 genotype 2a
(AAF59944) was superimposed on the known tertiary structure of the
variable region of humanized antibody (PDB:1FVD). Antibody is shown in
yellow (ribbon for beta sheet) with the location of E2 shown in red for
HVR1 (aa1–20 IMGT) or blue for the remainder of the Ig-like domain. All
the framework regions align within 2 A˚ of the kappa antibody peptide
chain. (B) The location of host protein sequence homology domains shown
for the primary structure of E2. Ig-like domains and PKR/eIF2a
phosphorylation domains are shown (numbering is from the amino terminus
of mature E2 protein).
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acids of a large group (see Methods) of Ig (heavy, kappa,
lambda) and TCR (a, h); thus, providing a measure of
sequence similarity to each group. Mutations that decreased
epitope binding of patient sera collected at various times
post infection, resulting in escape from immune recognition,
were seen to incrementally and significantly increase Ig
similarity scores with respect to Ig groups (P = 0.036 by
paired t test at 11 months relative to prior samples) or as an
average among all groups (comparison to 3496 sequences),
consistent with an improvement in Ig mimicry (Fig. 4B).
Similar trends in the evolution of mimicry were obtained
using alternative scoring matrices (data not shown for
identity, PAM250 and BLOSUM62 matrices). This meant
that each amino acid substitution that was selected in these
epitopes was either identical to, or more like, the corre-
sponding amino acids in the majority of individual Ig and
TCR molecules. The increases in score were greatest for
heavy and kappa chains that were equivalent to one amino
acid identity substitution (increase of 1500) in the epitope
region of HVR1. The 11-month immune escape epitope
variant avoided subsequent recognition by the immune
response, indicating that immune evasion and loss of
immunogenicity was directional with respect to the extent
of Ig molecular mimicry. This indicated that variation in
HVR1 was not only able to escape neutralizing antibody butalso to become non-immunogenic, coincident with the
acquisition of mutations that increased similarity to Ig and
TCR types consistent with a model of immune evasion
through mimicry.
In another of the few characterizations of HVR1 evo-
lution during immune evasion (Fig. 5A), similar increases
Fig. 5. Retrospective analysis of immune escape in experimentally infected
chimpanzees involves host-dependent evolution to increased Ig similarity.
(A) Sequence evolution of HVR1 region (aa1–20 IMGT) is shown for 3
persistently infected chimpanzees infected with a defined inoculum of HCV
1a (Peggy, Hans and Phil; (van Doorn et al., 1995) as well as a chimpanzee
infected with a defined inoculum of HCV 1 (Chimp #1) (Lu et al., 2001).
The detection of antibody formation is shown with initialed arrows for each
animal which corresponded with the onset of HVR1 evolution. Serocon-
version data was not available for Chimp #1. (B) Average Ig similarities
scores among immunoglobulin (heavy; light kappa and lambda) and TCRa
and TCRh were calculated over a 10- to 12-year period for 4 chimpanzees
with persistent HCV 1a or HCV 1 infections.
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study of experimentally HCV 1b infected chimpanzees
(van Doorn et al., 1995). Among a group of six
chimpanzees infected with a defined HCV 1b isolate, three
patterns of evolution were observed where half the animals
developed anti-HVR1 antibodies and resolved their infec-
tion without evolution of the HVR1 sequences (i.e., no
change in Ig similarity). Among the persistent infections,
one chimpanzee was not stimulated to produce antibody to
HVR1 until 7 years of chronic infection followed by a
single mutation in HVR1 that reduced the average Ig
similarity score, thus constituting a pattern of structural
stasis (Fig. 5B, Phil). Finally, for the two persistently
infected animals that seroconverted early, their HVR1
sequences concomitantly began to evolve to continuously
increase Ig mimicry and escape immunity (P = 0.000005
for similarity scores differences after seroconversion),
consistent with selection of this E2 region on the basis of
similarity to Ig proteins (Fig. 5B, Peggy and Hans).
Convergent evolution was seen for Peggy and Hans that
both independently acquired 3 common mutations that
increased Ig similarities (Fig. 5A).
A second independent follow-up study of an experimen-
tally HCV 1-infected chimp (Chimp #1) that developed a
persistent infection (Lu et al., 2001) showed that the extent
of mimicry stayed relatively constant through a 12-year
period of monitoring (Figs. 5A and B). The consensus
sequence incrementally acquired a group of 5 mutations that
resulted in an oscillation of Ig mimicry around a relatively
constant level suggesting that the virus was sufficiently
similar to the host Ig structures and maintained this level of
host mimicry.
Evolution of E2 mimicry during seroconversion and
interferon therapy
The current therapy for HCV infection involves treat-
ment with IFN and ribavirin (Kryczka and Zarebska-
Michaluk, 2003). Since the majority of patients become
IFN-resistant during treatment and this transformation is
associated with changes in HVR1 (Farci et al., 2000,
2002; Taylor et al., 2000), the evolution of HVR1 relative
to Ig was determined following natural infection, sero-
conversion and subsequent IFN treatment. HCV nucleic
acid testing of approximately 5 million Canadian blood
donors has detected the first, and to date only, blood
donor to be HCV positive prior to seroconversion (Patient
A), that was infected by a defined source patient (S). E2
molecular evolution was monitored before and during
seroconversion and the establishment of persistent infec-
tion (Larke et al., 2002), followed by an unresponsive IFN
treatment. E2 HVR1 sequence comparisons of molecular
clones (n = 117, Fig. 6A) from samples collected over this
time showed that multiple forms of variants with different
Ig similarity scores appeared until seroconversion and
persistent infection, when the most divergent viral variants
Fig. 6. Amino acid sequence analysis of cloned variants in HCV 1b populations in a nosocomial patient during the early phases of HCV primary infection and IFN
treatment (Larke et al., 2002). (A) Mutations in the E2 region (E2 aa8–72) are indicated relative to the source virus sequence (S1, direct sequence, (S-D)) for
sequences of clones in sequential patient samples from patient A. Dots indicate amino acid identity to the source virus, (S-D). The percentage prevalence of each
genotype is shown for each sequence in each population. (B) Viral load decreased on seroconversion and the establishment of persistent infection. RT-PCR products
of serially diluted viral RNA prepared as described in Methods are shown following gel electrophoresis; the location of the amplified DNA is indicated with an
arrow. Seroconversion was monitored by EIA and indicated as negative (), weak reactive (F) and positive (+). (C) Evolution of Ig similarity in HCV 1a
patient A (Pat-A) infected by a defined source patient S (Pat-S). Each symbol represents the similarity score for HVR1 (aa1–20 IMGT) of individual molecular
clones sampled at each time point. Ig similarity scores represent average scores among 5 groups of Ig and TCR molecules. (D) Evolution of Ig similarity in an
immunocompromised HCV 3a infected lung transplant patient infected from patient D (Pat-D). Each symbol represents the average of Ig group similarity
scores for HVR1 (aa1–20 IMGT) of individual molecular clones sampled at each time point. The patient letter and time of sampling is indicated for each viral
population.
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viruses having Ig scores similar to the source virus, (Fig.
6C). The sequence encompassing the amino terminal (1–
72 aa) region of E2 was quite homogeneous in the
quasispecies variants of the source virus (S1) from the
patient with chronic HCV infection, where 94% (16/17) of
the clones analyzed were almost identical, with the
remaining 6% of clones differing by more than six
substitutions (aa8–72 shown in Fig. 6A). There was
significantly more sequence variation seen in the variants
from the nosocomially infected patient (patient A), prior to
seroconversion, whereas 4 weeks after seroconversion, all
the clones in sample A 2.4 m (29/29) were found to be
identical or genetically similar in sequence to clones (V5
mutations) from the source virus (S1). The composition of
the quasispecies shifted significantly during the serocon-
version where the most divergent viral variants, disap-
peared after the development of antibody (P b 0.0004 by
Chi-square analysis). The quasispecies shift suggests that
two types of quasispecies variants co-existed during acute
infection, one was restricted (i.e., non-persistent form),
while the other became persistent after the selective
pressure of seroconversion (i.e., persistent forms of
variants with few or no mutations). The disappearance
of the majority of the more divergent variants coincided
with a N10-fold decrease in viral load (Fig. 6B) as HCV-
specific antibodies were fully developed in sample A 2.4
m (Fig. 6B). Although the population of persistent variants
selected after seroconversion in the A 2.4 m sample
possessed HVR1 sequences (IMGT aa1-20) that had not
increased in Ig similarity relative to the population of
viruses present prior to seroconversion, the least variant-
type viruses constituted a genetically distinct population
that resists negative selection by the immune response.
This suggests that variants that were not recognized and
eliminated by the immune response in patient A, and were
genetically similar to the source virus population, may
have possessed currently undefined, qualitative, or quanti-
tative properties of mimicry that mediated immune
evasion. However, IFN treatment of patient A resulted in
the selection of mutants with significantly increased
average Ig similarity scores (P = 4  1012) suggesting
a role for Ig mimicry in IFN resistance. Finally, as a
control, in the absence of an immune response and IFN
therapy, HVR1 evolution in an immunosuppressed lung
transplant patient involved fewer mutations and main-
tained relatively constant average Ig similarity (P N 0.05)
(Fig. 6D).Discussion
HCV E2 protein possesses neutralization epitopes
within HVR1. Although highly variable, HVR1 maintains
its conformation and charge (Penin et al., 2001) and also
demonstrates convergent evolution (Casino et al., 1999)which is evidence of positive selection and functional
importance (Brown et al., 2001). We provide structural
and sequence data to indicate that HCV mimics immuno-
globulins and furthermore that evolutionary change in the
extent of mimicry correlates with the host-dependent
ability of HCV to escape immune recognition. We thus
propose that HCV hides from the immune system by
assuming the structures of the most variable aspect of the
immune system itself (i.e., the variable region). Molecular
mimicry of host antibodies and TCR by HCV constitutes
a unique means of circumventing the immune response
because it is focused on the variable region of antibodies,
which are both the effectors as well as targets for humoral
immunity and thus constitute a family of tolerated
antigens. Host-like antigenic structures are non-immuno-
genic due to tolerance mechanisms that prevent the
synthesis of self-reactive antibodies (Rajewsky, 1996;
Starr et al., 2003). The structural diversity of the Ig
molecules makes them ideal targets for a flexible pattern
of mimicry by forms of E2 which may account for some
of the genotypic and quasispecies diversity seen among
HCV viruses. It also becomes possible to speculate that
E2, as a viral homologue of immunoglobulins, may func-
tion as an immunomodulator and affect the nature of the
immune response, including immune dysfunction of T,
NK, and dendritic cells (reviewed (Eisen-Vandervelde et
al., 2004) to further benefit HCV survival or replication.
This would extend the demonstration of structural
mimicry by viruses for immune evasion beyond the DNA
viruses that posses a large number of immunoglobulin
superfamily homologues, to RNA viruses that must be
much more conservative in their encoded molecular
mimics. The evolution of Ig mimicry not only provides
a mechanistic explanation of HVR1 variability and loss of
immunogenicity, but also insight into host-dependent
disease patterns.
Host-dependent evolution of Ig mimicry
Human Ig structure is dependent on both the expression
of specific germ-line alleles as well as adaptive somatic
mutations to result in multiple groups of v-gene variants
that could be characterized as quasispecies groups. If E2 is
adapting to a population of host molecular structures, it is
possible that E2 is either well or poorly matched to the
immune repertoire of a given host. If E2 meets or exceeds
the threshold of similarity needed to avoid detection, it will
not induce an immune response and thus not be driven by
antibody selection and would be expected to stay relatively
stable with respect to Ig mimicry. Alternatively, a poor
match to a novel immune repertoire will result in either a
clearance of virus if E2 cannot efficiently evolve to evade
immune detection (as seen for 15–20% of human
infections) or alternatively will adapt to more closely
match the new host environment. We thus expect 2
patterns for the evolution of mimicry in persistence; either
Y.-W. Hu et al. / Virology 332 (2005) 538–549546stasis with little or no evolution of Ig mimicry or increased
mimicry following seroconversion. Indeed, we found both
patterns of HVR1 evolution during persistent infection in
humans and experimentally infected chimpanzees.
Host-dependent correlations with clinical outcome have
been documented for HCV patients possessing specific
IgG (GM and KM) and HLA (Type I and II) allotypes
(Pandey et al., 2004; Thio et al., 2001, 2002; Thursz et
al., 1999). The relationship of persistent HCV infection
with Ig alleles may be due to differences in extent of
structural mimicry of HCV E2 proteins with specific
heavy (GM) and light (KM) allotypes or to possible
epistatic relationships with adjacent variable genes (Pan-
dey et al., 2004). Similarly, the ability of patients with
specific HLA type I and II allotypes to clear HCV infection
may involve specific structural relationships to specific
HLA molecules, which are also members of the immuno-
globulin superfamily.
The direct relationship between quasispecies complexity
and persistence is consistent with an increased probability of
mimicry to a given host where the greater the E2 structural
diversity, the greater the chance that effective levels of
mimicry exist to evade immune detection (Abbate et al.,
2003; Arenas et al., 2004).
Ig mimicry and IFN
Several studies have shown an association between
variation in HVR1 (Taylor et al., 2000) and resistance to
IFN indicating that functions of this region play a role in
circumventing the inhibitory effects of IFN. IFN treatment
of patient A resulted in the selection of mutants with
increased average Ig similarity scores suggesting a role for
Ig mimicry in IFN resistance. This observation is also
consistent with the correlation between IFN resistance and
a lack of immunogenicity (Del Porto et al., 2000;
Nakamoto et al., 1996) that could be due to increased
host mimicry. However, retrospective analysis of Ig
mimicry in several IFN-treated HCV patients (Boulestin
et al., 2002; Penin et al., 2001) showed both increased and
decreased similarity scores in IFN resistant variants
following multiple IFN treatments indicating that overall
average levels of immune mimicry (averaged among Ig and
TCR types) does not simply explain the variation in HVR1
of IFN resistant variants (unpublished data E.G. Brown, M.
Pelchat and Y.-W. Hu).
Ig mimicry and autoimmunity
Although it is believed that autoimmunity is initiated
when the host and infecting agent share genetic sequence
similarities (Oldstone, 1998, 2000), there are few demon-
strations of such homologies in RNA viruses. However,
studies show a role for antigenic mimicry of the human
immunodeficiency virus gp41 motif, GTDRV, with the
HLA II, GTERV, motif found in immune cells, wherecross-reactive antibodies promote immune dysfunction
(Powell et al., 2000). The identification of E2 protein
domains with homology to Ig provides the identification of
shared antigenic structures that may, through chronic
stimulation, induce autoimmune diseases such as mixed
type II cryoglobulinemia and others that are associated with
75% of chronic HCV infections (Dammacco et al., 2000;
Major et al., 2004). Additionally, there is a further
association between HCV patients with mixed type II
cryoglobulinemia and lymphoproliferative disease seen as
non-Hodgkin’s B-cell lymphoma, indicating a progression
of the former to the latter and that both thus implicate
chronic HCV antigenic stimulation (Dammacco et al.,
2000). Evidence of Ig mimicry now incriminates E2 as a
candidate antigen for the induction of autoimmunity.
Ig mimicry as a model for HCV persistence
The unique discovery of Ig mimicry by E2 provides a
model for virus-host co-evolution as a function of Ig
mimicry, where HCV possessing threshold levels of
mimicry can circumvent host reactions. In fact, Ig mimicry
may represent a general pattern of evolution among viruses
and significantly modify our understanding of viral immune
escape and persistence with implications to viral patho-
genesis and therapy. We present a hypothesis of Ig mimicry
that not only accounts for many facts about HCV infection,
but also provides a basis for further investigations of the
role of Ig-mimicry in HCV biology. Future character-
izations of the relationships between E2 and members of the
immunoglobulin superfamily may illuminate avenues for
diagnosis, treatment and prevention not the least of which is
immunization for which the viral receptor, E2, is an
important candidate.Methods
Patient samples
Two patients with primary HCV infections transmitted
from known virus sources were enrolled. Patient A had
acquired an acute nosocomial HCV 1a infection from
chronically infected patient S (Larke et al., 2002). Two
samples were obtained before and soon after seroconversion
(A0 and A 1.2 m at days 36 and 46 post infection (PI),
respectively) as well as sample A 2.4 m that was collected 4
weeks after seroconversion (day 72 PI). On day 74 pi, patient
A was treated with IFN and ribavirin for 6 months. Samples
were also collected 1 and 2 months after 6 months of IFN
treatment. Patient B was a lung transplant patient who had
cleared a previous HCV infection and subsequently acquired
HCV 3a from an organ donor (patient D). Serial samples
were taken from patient B; on days 8, 50, 78, 109, and 171
after transplant/infection. HVR1 sequences in published
follow-up studies in humans (Kato et al., 1994; Larke et
Y.-W. Hu et al. / Virology 332 (2005) 538–549 547al., 2002) and chimpanzees (Lu et al., 2001; van Doorn et al.,
1995) were analyzed.
Anti-HCV antibody testing
Anti-HCV was detected using an EIA (Ortho HCV
version 3.0 ELISA, Ortho Diagnostic Systems Inc., Raritan,
NJ or Abbott AxSym EIA) and confirmed using RIBA
(Chiron RIBA HCV 3.0 SIA, CHIRON, Emeryville, CA).
Cloning and sequencing
Viral RNA was extracted from plasma using the
QIAamp Viral RNA Kit (QIAGEN, Germany) for cDNA
synthesis used random hexamer primer (pd(N)6) and the
Amersham Pharmacia Biotech First-Strand cDNA Syn-
thesis Kit. Nested RT-PCR was used to amplify the E2
region before cloning and sequencing as described pre-
viously (Larke et al., 2002).
Computer analysis of E2 sequences
Viral sequences were derived from patient samples,
Genbank or the LANL HCV database (hcv.lanl.gov). Ig
genes were obtained from the NREF database. Sequences
were locally aligned using ClustalW v1.82 and BLAST
v2.2.6 followed by manual alignment according to the
IMGT numbering scheme (imgt.cines.fr, (Lefranc et al.,
2003)) which is approved by the Human Genome Organ-
ization (HUGO) Nomenclature Committee (HGNC). HVR1
sequences were then tested for Ig similarity (relative to
IMGT alignment files of the variable domains of human
heavy (n = 984); light kappa (n = 843); light lambda (n =
1212); TCRa (n = 111); and TCRh (n = 346) chains) using
a scoring system based on a position-specific scoring matrix
that quantifies the physical and chemical properties of aas.
Specifically, for a given region of comparison, the sim-
ilarities of each constituent aa to the corresponding position
of reference sequences, was multiplied by a value found in
the updated Dayhoff aa similarity matrix (Feng et al., 1984;
Jones et al., 1992), derived from the observed frequencies of
aa substitutions in related proteins which is a function of the
physical (size, charge, and hydropathy) and chemical
similarities between aas. Using this algorithm, similarity
scores range up to 1500/aa for identity (maximum score =
(1500 L); where L = sequence length). Other similarity
scoring matrices were used including an identity matrix,
PAM250 and the BLOSUM62 matrices. All the matrices
produced results supporting similar trends of change for
HVR1 evolution (not shown). The three-dimensional model
structure of the N-terminal portion of E2 was made using
the SWISS-MODEL server (Schwede et al., 2003) for HCV
genotype 2a (AAF59944) relative to the tertiary structure of
the variable domain of humanized antibody 4D5
(PDB:1FVD). The model image was generated with both
VMD v1.8.2 and Raster3D v2.6.Statistical analysis
Population prevalence of differences in mutant popula-
tions was determined by Chi-squared analysis and differ-
ences in Ig similarity scores were determined using the
Student’s t test.
Expression of recombinant HCV E2 proteins
Full length (aa1–322) or amino terminal regions of E2
genes (aa1–113 or 123) from HCV 1a and 3a variants were
inserted into the baculovirus expression vector using the
BaculoGold kit (BD Biosciences, Mississauga, Canada) as
described previously (Hu et al., 1996) or the pET17a vector
for expression in E. coli as indicated by the manufacturer
(Novagen, San Diego). A methionine and six histidines
were added to the N-terminus of each construct. Forms of
E2 protein isolated from Patient A and B were expressed in
Spodoptera frugiperda (Sf9) insect cells and in E. coli BL21
cells induced with IPTG. Expressed protein sequences are in
a Supplementary note.
Western blotting
Western blotting was carried out using equal amounts of
crude protein lysates as previously described (Hu et al.,
1996). Recombinant protein expression levels were assessed
using anti-histidine (His) antibody staining (1:5000 dilution
of 6 His monoclonal antibody, BD Biosciences, US) and
secondary antibody, alkaline phosphatase conjugated anti-
mouse polyvalent immunoglobulins (1:15000 dilution,
Sigma, US) or alternatively were stained with Coomassie
blue. Recombinant E2 proteins were also reacted with
commercial preparations of alkaline phosphatase conjugated
goat antibodies raised against the Fab fragment of human
IgG, (binding was also obtained with goat antibodies
against whole human IgG, not shown) (catalogue no.
A8542 and A3312, respectively, Sigma-Aldrich Canada
Ltd.). Antibody was visualized by development with NBT
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